NTLA FY2027 EPS Increased by Brookline Capital Management

Key Points

• Brookline Capital Management raised its FY2027 EPS estimates for Intellia Therapeutics from $25.52 to $25.71, despite a current consensus estimate of a significant loss of ($5.07) per share.
• Intellia reported $14.25 million in quarterly revenue, surpassing estimates, and achieved a smaller loss per share than expected, at ($0.99), compared to a consensus of ($1.03).
• Despite recent positive earnings news, investor sentiment appears mixed, with analysts giving the stock a "Moderate Buy" rating and a price target average of $31.11, while some firms have lowered their price targets significantly.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Analysts at Brookline Capital Management boosted their FY2027 EPS estimates for shares of Intellia Therapeutics in a research note issued on Thursday, August 7th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of $25.71 for the year, up from their previous estimate of $25.52. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.04. The company had revenue of $14.25 million during the quarter, compared to analyst estimates of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 54.90%. Intellia Therapeutics's revenue for the quarter was up 104.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.52) EPS.

NTLA has been the subject of several other research reports. Citigroup lowered their price objective on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Chardan Capital restated a "buy" rating and set a $68.00 price target on shares of Intellia Therapeutics in a research note on Friday, May 9th. Royal Bank Of Canada decreased their price target on shares of Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating for the company in a research note on Friday. Canaccord Genuity Group decreased their price target on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research note on Tuesday, June 3rd. Finally, Wedbush restated a "neutral" rating and set a $7.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 16th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $31.11.

Intellia Therapeutics Stock Down 5.8%

NASDAQ:NTLA opened at $10.79 on Monday. The company has a fifty day moving average of $10.55 and a 200-day moving average of $9.49. The firm has a market capitalization of $1.12 billion, a P/E ratio of -2.30 and a beta of 2.31. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $24.16.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. raised its stake in Intellia Therapeutics by 51.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company's stock valued at $140,000 after acquiring an additional 6,722 shares during the period. D.A. Davidson & CO. raised its stake in Intellia Therapeutics by 76.2% in the 1st quarter. D.A. Davidson & CO. now owns 26,020 shares of the company's stock valued at $185,000 after acquiring an additional 11,250 shares during the period. California State Teachers Retirement System raised its stake in Intellia Therapeutics by 4.1% in the 4th quarter. California State Teachers Retirement System now owns 90,638 shares of the company's stock valued at $1,057,000 after acquiring an additional 3,596 shares during the period. Raymond James Financial Inc. bought a new stake in Intellia Therapeutics in the 4th quarter valued at about $4,793,000. Finally, Baker BROS. Advisors LP bought a new stake in shares of Intellia Therapeutics during the fourth quarter valued at about $7,510,000. 88.77% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total value of $104,617.24. Following the transaction, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. The trade was a 6.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 12,534 shares of company stock valued at $153,837. 3.10% of the stock is currently owned by insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.